External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EAN 2023

-
Coming soon
02:00 PM
Duration 5mins ePoster area
FIREFISH Parts 1 and 2: 48-month efficacy and safety of risdiplam▼ in Type 1 spinal muscular atrophy (SMA)
M Mazurkiewicz-Beldzinska, G Baranello, O Boespflug-Tanguy, JW Day, N Deconinck, A Klein, R Masson, E Mercuri, K Rose, L Servais, D Vlodavets, H Xiong, E Zanoteli, M El-Khairi, M Gerber, K Gorni, H Kletzl, L Palfreeman, A Dodman, BT Darras

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins ePoster area
SUNFISH Parts 1 and 2: 4-year efficacy and safety data of risdiplam▼ in Types 2 and 3 spinal muscular atrophy (SMA)
A Kostera-Pruszczyk, JW Day, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner, L Servais, J Braid, M Gerber, K Gorni, C Martin, WY Yeung, RS Scalco, E Mercuri

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar